About the authors: Co-first author, Kyle Garland earned his Ph.D. in Chemical Engineering in 2021 under the direction of Prof. John Wilson and is currently working for Brooklyn Immunotherapeutics, Inc. in San Diego, California as an R&D scientist investigating in vivo gene editing. His dissertation focused on the development of innate immune activators for local cancer therapy applications. Co-first author, Taylor Sheehy is working on her Ph.D. in Biomedical Engineering also under the direction of Prof. John Wilson. Her graduate work is centered around the development of molecularly engineered STING agonist delivery technologies to improve cancer immunotherapy. In this recently published review article, they provide a concise summary of the stimulator of interferon genes (STING) cellular signaling pathway and also highlight its significance in the context of cancer immunotherapy. Moreover, the authors offer a critical analysis of the chemical strategies that are being employed to enhance the efficacy, safety, and/or clinical utility of STING pathway agonists for the treatment of cancer.